Atorvastatin vs Simvastatin
## Overview
Atorvastatin and simvastatin are both widely used statins, but atorvastatin is a fully synthetic compound while simvastatin is a semisynthetic prodrug derived from lovastatin. Atorvastatin is substantially more potent and has a longer half-life.
## Mechanism of Action
Both inhibit HMG-CoA reductase competitively. Simvastatin is a prodrug lactone hydrolyzed in vivo to its active hydroxy acid form. Atorvastatin is administered as the active acid directly.
## Pharmacokinetics
Simvastatin has poor bioavailability (~5%) due to extensive first-pass metabolism entirely via CYP3A4. Its half-life is only 2–3 hours, necessitating evening dosing to coincide with peak nocturnal cholesterol synthesis. Atorvastatin's longer half-life (14 h) allows flexible dosing timing without loss of efficacy.
## Pharmacodynamics
Atorvastatin produces 37–51% LDL-C reduction across its dose range; simvastatin achieves 26–47% but is capped at 40 mg in most patients due to myopathy risk at 80 mg (FDA 2011 label update). The 80 mg simvastatin dose is restricted to patients already tolerating it for ≥12 months without evidence of myopathy.
## Clinical Evidence
The 4S trial established simvastatin as a landmark secondary prevention agent. HPS (Heart Protection Study) with simvastatin 40 mg demonstrated broad benefit across high-risk patients regardless of baseline LDL. Atorvastatin is supported by TNT (80 vs 10 mg), showing incremental benefit from high-intensity dosing.
## Safety
Simvastatin at 80 mg carries a significantly elevated myopathy/rhabdomyolysis risk, especially when combined with CYP3A4 inhibitors (e.g., amiodarone, verapamil, diltiazem, amlodipine limits simvastatin to 20 mg). Atorvastatin at equivalent doses is better tolerated.
## Key Takeaways
- Atorvastatin is more potent and has flexible dosing timing
- Simvastatin 80 mg is restricted due to myopathy; avoid in new patients
- Both are CYP3A4 substrates with significant drug interaction profiles
- Atorvastatin has superseded simvastatin as the preferred high-intensity option
निष्कर्ष
Atorvastatin is generally preferred over simvastatin for new prescriptions requiring high-intensity statin therapy. Simvastatin remains appropriate at moderate doses (20–40 mg) for patients who tolerate it and do not require maximum LDL-C reduction.